Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, breaks down how to communicate the value of ...

Biological drugs have been a game-changer for people with severe asthma, helping them breathe easier and live more ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...